Teladoc (TDOC) PT Raised to $28 at Chardan Capital Markets Following 4Q Top-Line and Bottom-Line Beats

Chardan Capital Markets analyst Steven Wardell raised its price target on Teladoc (NYSE: TDOC) to $28.00 (from $24.00) while maintaining a Buy rating, as the company reported 2016 fourth quarter results above consensus, offering top-line and bottom-line beats.

Wardell comments, "After market close on Wed., TDOC reported earnings with a beat and a mixed guide for 2017. For 4Q16, Teladoc beat the Street consensus by 2% on the topline and by $0.04 on the bottom line. Management guided to topline growth in 2017 of 48%, in-line with Street consensus and re-affirmed its target of being adj. EBITDA breakeven in 4Q17. Management also guided to more EBITDA loss in 2017 than the Street expected in the first 3 quarters driven by various investments in growth. We adjust our estimates down slightly and in-line with Management Guidance for 2017. We raise our PT to $28 based on multiple expansion we see in 2017 as TDOC's operating characteristics improve relative to valuation comps and investor confidence grows in the company's execution."

You May Also Be Interested In

• Natera (NTRA) PT Raised to $270 at BTIG
• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cytokinetics (CYTK) PT Raised to $118 at Mizuho